These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 32244015)

  • 21. Pathologic Features of Anti-Mi-2 Dermatomyositis.
    Tanboon J; Inoue M; Hirakawa S; Tachimori H; Hayashi S; Noguchi S; Suzuki S; Okiyama N; Fujimoto M; Nishino I
    Neurology; 2021 Jan; 96(3):e448-e459. PubMed ID: 33277422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased interleukin-9 levels in sera, muscle and skin of patients with dermatomyositis.
    Oishi K; Matsushita T; Takehara K; Hamaguchi Y
    J Dermatol; 2018 Aug; 45(8):1023-1025. PubMed ID: 30133800
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dermatomyositis and Autoantibodies].
    Fujimoto M
    Brain Nerve; 2018 Apr; 70(4):427-438. PubMed ID: 29632290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A single-center, retrospective record review of malignancy prevalence in patients with dermatomyositis with anti-transcription intermediary factor 1γ antibodies via line immunoassay versus immunoprecipitation.
    Westerdahl S; Hull CM; Clarke JT; Hansen CB; Rhoads JLW
    J Am Acad Dermatol; 2021 Feb; 84(2):559-561. PubMed ID: 32619611
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.
    Ikeda N; Yamaguchi Y; Kanaoka M; Ototake Y; Akita A; Watanabe T; Aihara M
    J Dermatol; 2020 May; 47(5):490-496. PubMed ID: 32103537
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Implications in the difference of anti-Mi-2 and -p155/140 autoantibody prevalence in two dermatomyositis cohorts from Mexico City and Guadalajara.
    Petri MH; Satoh M; Martin-Marquez BT; Vargas-Ramírez R; Jara LJ; Saavedra MA; Cruz-Gonzalez C; Andrade-Ortega L; Vera-Lastra O; Salazar-Páramo M; Prieto-Parra RE; Gonzalez-Lopez L; Gamez-Nava JI; Ramírez-Sánchez HU; Chan JY; Ross SJ; Chan EK; Vázquez-Del Mercado M
    Arthritis Res Ther; 2013 Apr; 15(2):R48. PubMed ID: 23557279
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of the dermatomyositis autoantigen Mi-2 in regenerating muscle.
    Mammen AL; Casciola-Rosen LA; Hall JC; Christopher-Stine L; Corse AM; Rosen A
    Arthritis Rheum; 2009 Dec; 60(12):3784-93. PubMed ID: 19950298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups.
    Nguyen M; Do V; Yell PC; Jo C; Liu J; Burns DK; Wright T; Cai C
    Acta Neuropathol Commun; 2020 Aug; 8(1):125. PubMed ID: 32758284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.
    Wolstencroft PW; Fiorentino DF
    Curr Rheumatol Rep; 2018 Apr; 20(5):28. PubMed ID: 29637414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unilateral heliotrope rash: a warning sign for anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis.
    Kume M; Arase N; Okiyama N; Koguchi-Yoshioka H; Tada T; Saruban H; Fujimoto M
    Rheumatology (Oxford); 2021 Apr; 60(4):e134-e135. PubMed ID: 33197263
    [No Abstract]   [Full Text] [Related]  

  • 31. Hyperacute muscle weakness in an unusual coexistence of antisignal recognition particle and anti-Mi-2 antibodies.
    Akintayo RO; Agbola OF; Adeyemo AW; Adelowo O
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28720599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dermatomyositis: An Update on Diagnosis and Treatment.
    Cobos GA; Femia A; Vleugels RA
    Am J Clin Dermatol; 2020 Jun; 21(3):339-353. PubMed ID: 32096127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
    Best M; Molinari N; Chasset F; Vincent T; Cordel N; Bessis D
    Acta Derm Venereol; 2019 Mar; 99(3):256-262. PubMed ID: 30460368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strong correlation between cancer progression and anti-transcription intermediary factor 1γ antibodies in dermatomyositis patients.
    Ogawa-Momohara M; Muro Y; Mitsuma T; Katayama M; Yanaba K; Nara M; Kakeda M; Kono M; Akiyama M
    Clin Exp Rheumatol; 2018; 36(6):990-995. PubMed ID: 29745874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical manifestations of skin, lung and muscle diseases in dermatomyositis positive for anti-aminoacyl tRNA synthetase antibodies.
    Fukamatsu H; Hirai Y; Miyake T; Kaji T; Morizane S; Yokoyama E; Hamada T; Oono T; Koyama Y; Norikane S; Iwatsuki K
    J Dermatol; 2019 Oct; 46(10):886-897. PubMed ID: 31418479
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic and Tissue Inflammation in Juvenile Dermatomyositis: From Pathogenesis to the Quest for Monitoring Tools.
    Wienke J; Deakin CT; Wedderburn LR; van Wijk F; van Royen-Kerkhof A
    Front Immunol; 2018; 9():2951. PubMed ID: 30619311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myositis-specific and myositis-associated autoantibodies in Indian patients with inflammatory myositis.
    Srivastava P; Dwivedi S; Misra R
    Rheumatol Int; 2016 Jul; 36(7):935-43. PubMed ID: 27193471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
    Aussy A; Fréret M; Gallay L; Bessis D; Vincent T; Jullien D; Drouot L; Jouen F; Joly P; Marie I; Meyer A; Sibilia J; Bader-Meunier B; Hachulla E; Hamidou M; Huë S; Charuel JL; Fabien N; Viailly PJ; Allenbach Y; Benveniste O; Cordel N; Boyer O;
    Arthritis Rheumatol; 2019 Aug; 71(8):1360-1370. PubMed ID: 30896088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].
    Bodoki L; Budai D; Nagy-Vincze M; Griger Z; Betteridge Z; Dankó K
    Orv Hetil; 2015 Sep; 156(36):1451-9. PubMed ID: 26320599
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies to Mi-2 alpha and Mi-2 beta in patients with idiopathic inflammatory myopathy.
    Richards M; García-De La Torre I; González-Bello YC; Vázquez-Del Mercado M; Andrade-Ortega L; Medrano-Ramírez G; Navarro-Zarza JE; Maradiaga-Ceceña M; Loyo E; Rojo-Mejía A; Gómez G; Seaman A; Fritzler MJ; Koenig M; Mahler M
    Rheumatology (Oxford); 2019 Sep; 58(9):1655-1661. PubMed ID: 30938432
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.